Full-Time

Executive Director

Global Site & Study Operations

Posted on 9/11/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$263.8k - $356.9k/yr

+ Annual bonus + Stock-based long-term incentives

Los Angeles, CA, USA + 1 more

More locations: Thousand Oaks, CA, USA

Remote

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Doctorate degree and 6 years of global site study experience, or a master's degree and 10 years of global site study experience, or a bachelor's degree and 12 years of global site study experience.
  • At least 6 years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs, or directing resource allocation.
  • Bachelor's degree in life sciences, pharmacy, nursing, medicine, or a related discipline; an advanced degree is preferred.
  • 15+ years of progressive experience in pharmaceutical, biotechnology, contract research organization, or clinical research organizations.
  • Extensive clinical operations and study management experience across multiple phases of clinical development.
  • Significant leadership experience managing managers and/or large, geographically distributed clinical operations organizations, including a monitoring organization.
  • Demonstrated experience overseeing complex global or regional clinical trial portfolios.
  • Demonstrated experience with contract research organization and vendor governance, outsourcing models, budget management, and resource planning.
  • A track record of leading organizational change and improving clinical operations performance.
  • Strong knowledge of ICH-GCP, clinical development processes, and applicable regulatory requirements, including experience supporting regulatory inspections and clinical quality management.
  • Experience working for or overseeing clinical research vendors, including contract research organizations, central laboratories, and imaging vendors.
  • Experience managing clinical operations across the relevant geography or region, including strong understanding of local regulatory requirements for clinical trials.
  • Ability to navigate cross-geographic and cultural dynamics and lead efficient global teams.
  • Experience delivering portfolio- or cross-study-level budgets, timelines, and performance metrics aligned with global and functional priorities.
  • Ability to oversee resource and budget allocation in accordance with functional financial principles and global clinical priorities.
  • Experience assessing internal capabilities, identifying key capabilities, and leading continuous-improvement initiatives with cross-functional adoption.
  • Experience leading organizations through cross-functional change initiatives, solving complex problems, driving innovation, and evolving strategies and structures.
  • Ability to build partnerships with Clinical Development, Medical, Regulatory Affairs, Safety, Biometrics, Data Management, Clinical Supply, Quality, and other functions.
  • Ability to communicate portfolio performance, risks, and strategic recommendations clearly to senior leadership.
Responsibilities
  • Oversee countries and regions within the Americas, including the United States, Canada, and Latin America.
  • Provide enterprise-level strategic leadership, operational accountability, people leadership, and cross-functional influence for regional Study and Site Operations.
  • Initiate, manage, ensure quality for, and complete Phase I-IV clinical trials in the region in compliance with ICH-GCP, regulatory requirements, and company policies.
  • Guide the organization on modern site-monitoring approaches and associated resource strategies.
  • Represent the region and/or Global Site and Study Operations in enterprise forums and provide insights for portfolio, program, and study-planning decisions.
  • Build and develop a high-performing Country/Hub Head team as strategic leaders and create a culture of accountability, innovation, and operational excellence.
  • Champion innovation and continuous improvement in study start-up approaches by embedding digital solutions, predictive analytics, and harmonized ways of working.
  • Implement the Regional Study and Site Operations strategy and allocate study resources according to global operations and priorities.
  • Optimize deployment of internal and augmented staff across clinical programs.
  • Interpret and cascade Global Development Operations strategies into consistent regional and country-level delivery of studies, site engagement, monitoring, and cross-functional processes.
  • Provide executive oversight of high-risk or strategically important clinical programs.
  • Act as the escalation point for study risks and issues, coach teams through mitigation strategies and scenario planning, and ensure timely resolution and visibility.
  • Build and sustain a clinical research associate monitoring organization, including resourcing strategies and portfolio considerations.
  • Ensure monitoring strategies use centralized monitoring, on-site and remote monitoring, targeted source document review/source data verification, and risk and quality indicators and thresholds as appropriate.
  • Lead the evolving site-engagement model to strengthen clinical research site relationships, improve site experience, and enhance site performance.
  • Make decisions on regional study and site operations, including resource allocation, budget utilization, and vendor performance.
  • Maintain oversight of the regional clinical trial portfolio through study start-up, enrollment, execution, database lock, and study closeout.
  • Coach and mentor teams in managing challenges and escalating issues.
  • Ensure inspection readiness throughout the clinical trial lifecycle and follow through on regional audits and inspections.
  • Represent Global Site and Study Operations and/or the region in global governance bodies with delegated authority over portfolio decisions, timelines, and resourcing.
  • Lead, coach, and develop regional and country Study and Site Operations leaders, including performance management, succession planning, and leadership-bench development.
  • Build the organizational capabilities, resourcing, and operating model required for current and future regional portfolio needs.
  • Foster a high-performing, inclusive, accountable, and patient-focused culture across geographically distributed teams.
  • Lead organizational change and enable adoption of new operating models, technologies, monitoring approaches, and clinical development practices.
  • Identify opportunities to simplify processes, improve productivity, and increase predictability of clinical trial delivery.
  • Use data and performance insights to drive decisions and continuous improvement.
  • Lead or sponsor regional and global clinical operations transformation initiatives.
  • Promote a center-of-excellence mindset and global knowledge sharing and best-practice adoption.
  • Partner with leaders across Clinical Development, Operations, Regulatory, and regional organizations to align study start-up strategy and execution resources.
  • Act as a visible change leader and promote Global Site and Study Operations as a strategic enabler of predictable clinical trial execution.
  • Cultivate leadership and capability across geographies to build resilient, empowered teams.
  • Set regional delivery goals, operating expectations, and performance standards across study start-up, site engagement, monitoring, execution, and closeout.
  • Build talent and capabilities, manage performance, and act as a liaison for cultural differences within the region.
Desired Qualifications
  • An advanced degree.
  • 15+ years of progressive experience in pharmaceutical, biotechnology, contract research organization, or clinical research organizations.
  • Extensive clinical operations and study management experience across multiple phases of clinical development.
  • Significant experience managing managers and/or large, geographically distributed clinical operations organizations, including a monitoring organization.
  • Experience overseeing complex global or regional clinical trial portfolios.
  • Experience with contract research organization/vendor governance, outsourcing models, budget management, and resource planning.
  • A track record of leading organizational change and improving clinical operations performance.
  • Strong knowledge of ICH-GCP, clinical development processes, regulatory requirements, regulatory inspections, and clinical quality management.
  • Experience working for or overseeing clinical research vendors such as contract research organizations, central laboratories, and imaging vendors.
  • Experience managing clinical operations across the relevant geography or region and understanding local clinical-trial regulatory requirements.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.